This brochure positions Clario as a single-vendor solution for assessing efficacy, safety, and quality of life in biotech clinical trials. It describes an integrated portfolio spanning eCOA, cardiac, respiratory, imaging, precision motion, and clinical adjudication endpoints. The document emphasizes Clario’s scientific expertise, operational excellence, and advanced technology, including AI-driven analytics and a unified platform. With over 60% of FDA drug approvals supported since 2012, Clario highlights its proven impact and reliability. The brochure focuses on reducing complexity, accelerating timelines, and delivering regulatory-ready data through coordinated global teams and participant-centric trial execution.

Join for free to read